Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Sponsor
Tanabe Pharma Corporation
Study ID
NCT02220907
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.

Key Dates

Start date
Aug 31, 2014
Status verified
Dec 2025
Primary completion
Feb 29, 2016
Completion
Feb 29, 2016

Study Design

Enrollment
153 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Teneligliptin/Canagliflozin
    Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.

Primary Outcome Measure

Number of Participants With Adverse Events [ Time Frame: 52 Weeks ]

Related Studies